DRIVEN in re: to ur post 2 me..Dr. Joseph Rubinfeld..this is for the 100+ private messages I got yesterday.. This comes off GNBT website price .02 & has 10+ institutional investors that well due ur DD. I can put a lot more up but people wanted to know why I sold..this plus a lot more but I still luv ambs. 1 last thing..if u read Rubenfeld statement he uses the word IF IF IF IF .. I can say IF kool aid works it could also cure pneumonia.
This comes off of GNBT website & I also bought into that story too. If anyone wants more ask & I will provide info all day.
In addition to his efforts in founding Amgen, Dr. Rubinfeld has a fifty year history in pharmaceutical and consumer product development. His accomplishments include the development of the multi-billion dollar antibiotic Amoxicillin as well as the invention and development of the first synthetic biodegradable detergent. In 1984 Dr. Rubinfeld won the prestigious Common Wealth Award for Science and Invention. This award was a testament to his proclivity for achieving major inventions, represented by the numerous patents obtained during his distinguished career.
Dr. Rubinfeld began his career as a research scientist with several pharmaceutical and consumer product companies including Schering Plough, Colgate Palmolive and Upjohn. He served for twelve years at Bristol Myers, where in addition to developing Amoxicillin and Cefadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. After co-founding Amgen in 1980 and serving as its Chief of Operations, Dr. Rubinfeld also co-founded the IBA (Industrial Biotechnology Association) in 1981, which was the precursor to today's BIO (Biotechnology Industry Organization). He has also served as an advisor or board member to a number of biotech companies including AVI BioPharma, Quark Pharmaceuticals, and Cytrx Corporation. In 1991 he founded Supergen, a drug development company based in Dublin, California, where he served as Chairman, CEO and President until 2003 and as a member of the board of directors until 2005. During that time he oversaw the company's initial public offering and its rise to a multi-billion dollar market capitalization , fueled by the commercialization of four anti-cancer drugs, including Pentostatin and Decitabine, and the issuance of over 20 drug patents in his name.
AI
